IPO
IPO filing, visualized

TRex Bio, Inc.

TRXB · Nasdaq424B4 · Oct 9, 2026Priced Oct 8, 2026

Priced Oct 8, 2026 · range was $14–$16 · latest SEC filing Nov 13, 2026.

Pinch-zoom for details.

The offering

Final price
$14.00
per share, from the final prospectus
Shares offered
8.33M
+1.25M over-allotment option
Raise at the final price
$117M
8,333,334 × $14, before fees

What the company does

Clinical-stage biotech developing medicines based on tissue regulatory T cells (Tregs) to restore immune balance in autoimmune and inflammatory diseases.

Things to weigh

  • The filing's financial tables couldn't be read reliably, so none are shown here.

Risks

  1. We are a clinical-stage biopharmaceutical company with a limited operating history…
  2. Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering…
  3. Clinical development is lengthy and expensive, characterized by uncertain outcomes, with results of earlier studies…
  4. Delays or difficulties in the enrollment and dosing of patients in clinical trials delay or prevent receipt of necessary regulatory approvals
  5. Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval…
  6. We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for…

The filing's own risk-factor headings, shortened.

Strategy

The filing doesn't set out its strategy in a list we could read.

Source: TRex Bio, Inc.'s Form 424B4, filed with the SEC on Oct 9, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.